2024-10-27 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison:**

Eli Lilly and Co (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 856.19% compared to the S&P 500's 135.48%. This represents a substantial divergence of 720.71%, placing it in the 89.53% percentile of its historical performance against the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $891.32 (Last-market: $892.61)
* **5-Day Moving Average:** $905.56
* **20-Day Moving Average:** $904.54
* **60-Day Moving Average:** $907.06

The stock is currently trading slightly below its 5-day and 20-day moving averages, suggesting potential short-term weakness. However, it remains above the 60-day moving average, indicating a longer-term uptrend.

**3. Technical Indicators:**

* **RSI:** 51.75 -  The RSI is in neutral territory, indicating neither overbought nor oversold conditions.
* **PPO:** -0.17 -  The PPO is negative, suggesting a potential downtrend, though it's not a strong signal.
* **Delta_Previous_Relative_Divergence:** -2.95 -  This indicates a short-term decline in relative performance.
* **Expected Return:** 96.56% -  This suggests a strong potential for outperformance compared to the S&P 500 over the long term (2 years+).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | $11.30B |
| 2024-04-30 | 2.49 | $8.77B |
| 2023-11-02 | -0.06 | $9.50B |
| 2023-08-08 | 1.96 | $8.31B |
| 2024-08-08 | 1.96 | $8.31B |

The latest earnings report (2024-08-08) showed an EPS of $3.29, exceeding analyst expectations. Revenue also came in above forecasts at $11.30B. This strong performance reinforces Eli Lilly's robust growth trajectory.

**5. News and Recent Issues:**

* **Recent Earnings News:**  Eli Lilly's recent earnings beat expectations, boosting investor confidence and driving a positive market outlook.
* **Analyst Opinions:**  Finbold reports a strong consensus among analysts with a "Buy" rating and a price target of $950. This indicates a significant upside potential for the stock. 
* **Performance Highlights:**  Eli Lilly continues to excel with its innovative drug portfolio, particularly in diabetes and Alzheimer's treatments. Its robust pipeline of new products further solidifies its position as a leading pharmaceutical company.

**6. Comprehensive Analysis:**

Eli Lilly and Co (LLY) is a leading pharmaceutical company with a strong track record of outperforming the market. Recent earnings results exceeded expectations, confirming the company's robust growth trajectory. Technical indicators suggest a potential short-term correction but the long-term outlook remains positive. Analysts are optimistic about the company's future prospects, with a strong consensus "Buy" rating and a target price significantly higher than current levels. Investors looking for long-term growth and outperformance potential may consider adding LLY to their portfolio. 
